THALES
28.5.2024 12:01:28 CEST | Business Wire | Press release
Thales unveils FlytEDGE, a revolutionary connected cloud-based inflight entertainment system that will transform passenger engagement to the extraordinary. FlytEDGE is not like a traditional IFE system — with a sleek architecture, cutting-edge features, and unparalleled performance it enables airlines to stand out by bringing the ‘cool’ factor to each seat, offering fully-tailored passenger interactions:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528532879/en/
(Photo: Thales)
- Live personalization for a journey filled with unique experiences
- Instantly stream favorites and never miss a beat, continue watching on all flights
- Immense volume of content to immerse passengers in a world of entertainment choices
Creating personalized experiences
Personalization is at the heart of FlytEDGE. Every passenger is one-of-a-kind and the system empowers airlines to recommend experiences tailored to each person's preferences. FlytEDGE is a true engagement platform offering boundless opportunities for connected and custom journeys. FlytEDGE delivers ‘just-for-you’ experiences never seen before. The system intelligently recommends content across domains, with an individually tailored and immersive entertainment experience.
Delivering the future of entertainment to each passenger
FlytEDGE is the IFEC industry’s first solution to feature edge caching. Passengers can now instantly stream their favorite entertainment using their personal video subscriptions and continue watching their favorite shows from the ground to the air and across flights.
Leveraging a state-of-the-art connected cloud architecture, the system breaks through barriers providing airlines with unparalleled flexibility to rapidly bring in any web-based service.
- Top game providers for interactive options that will captivate from take-off to touch down
- Video streamers that go beyond the blockbuster to bring infinite bingeable choices to passengers
With FlytEDGE airlines can integrate partners at the speed of consumer technology to create exhilarating experiences at the forefront of inflight entertainment.
Thales’ FlytEDGE solution features the best consumer technologies on the market. The system boasts cinematic 4K QLED HDR seatback displays to immerse passengers with over 1 billon vibrant colors and two Bluetooth® connections so passengers can pair their personal wireless devices. The system broadcasts the same user interface onboard for all devices- phones, tablets and seatback screens. With Thales’ Crystal Cabin® award-winning power solution delivering high-speed charging at each seat to any passenger device, everyone arrives at their destination recharged, entertained, and relaxed.
Value for airline customers
FlytEDGE features the Crystal Cabin® award-winning Onboard Data Center (ODC) with 96TB of storage to enable on-board edge caching, this solution reduces connectivity consumption and ensures bandwidth is available for other inflight services. No matter how many people watch the same content, each title streams once to the aircraft allowing passengers to instantly access endless entertainment.
The ODC takes the IFE system performance to new heights.
- Replaces the traditional multi-server network with an effective and compact blade architecture
- Simplifies upgradeability path with easy blade swaps
- Ensures the highest system availability
FlytEDGE goes beyond the hardware by redefining software and content updates to reduce cost and lead-time.
- Exceptional Efficiency – Remote operations with virtual labs for anywhere, anytime updates
- Superior Performance – Real-time system monitoring and automated maintenance tasks
- Scalable and Evolving – Continuous integration of new services for a system that is always growing at the speed of consumer technologies
FlytEDGE is already flying! We’re just at the beginning of what’s possible with a fully connected cloud platform. FlytEDGE’s game-changing features and intuitive functionality sets it light-years ahead of the competition. Bringing Thales’ FlytEDGE technology to the airline industry means an in-flight experience that is as eagerly awaited as the destination itself, and there’s so much more to look forward to. It is time to embrace the EDGE.
“At Thales we’re always at the forefront of innovation, investing in digital technologies, and working with our partners to redefine the inflight experience. We’re delighted to bring FlytEDGE’s state-of-the-art capabilities to our airline customers to create memorable and fully-tailored passenger interactions.” said Yannick Assouad, Executive Vice-President Avionics, Thales. “FlytEDGE is the first connected cloud-based IFE to introduce ground-breaking new experiences with a true engagement platform offering boundless opportunities for unique journeys. Stay tuned for more exciting news as the system is set to premier on a leading global airline.”
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Cybersecurity and Digital Identity. It develops products and solutions that help make the world safer, greener and more inclusive.
The Group invests close to €4 billion a year in Research & Development, particularly in key innovation areas such as AI, cybersecurity, quantum technologies, cloud technologies and 6G.
Thales has 81,000* employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.
* These figures exclude the ground transportation business, which is being divested
PLEASE VISIT
Thales Group
Thales InFlyt Experience
X @Thalesgroup
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528532879/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
